Double Blind Placebo Controlled Study to Assess Efficacy and Safety of a Combined Allergen Vaccine (CYT005-AllQbG10) and Its Single Components in Patients With House Dust Mite Allergy

Trial Profile

Double Blind Placebo Controlled Study to Assess Efficacy and Safety of a Combined Allergen Vaccine (CYT005-AllQbG10) and Its Single Components in Patients With House Dust Mite Allergy

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2013

At a glance

  • Drugs CMP 001; CYT 005 AllQbG10; House dust mite allergy immunotherapy
  • Indications Allergic rhinitis
  • Focus Adverse reactions
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 19 Feb 2008 The expected completion date for this trial is now 1 Mar 2008.
    • 14 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top